R
Rene-Olivier Casasnovas
Researcher at University of Burgundy
Publications - 107
Citations - 4647
Rene-Olivier Casasnovas is an academic researcher from University of Burgundy. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 30, co-authored 82 publications receiving 3785 citations.
Papers
More filters
Journal ArticleDOI
Omitting Radiotherapy in Early Positron Emission Tomography–Negative Stage I/II Hodgkin Lymphoma Is Associated With an Increased Risk of Early Relapse: Clinical Results of the Preplanned Interim Analysis of the Randomized EORTC/LYSA/FIL H10 Trial
John M. M. Raemaekers,Marc André,Massimo Federico,Theodore Girinsky,Reman Oumedaly,Ercole Brusamolino,Pauline Brice,Christophe Fermé,Richard W.M. van der Maazen,Manuel Gotti,Reda Bouabdallah,Catherine Sebban,Yolande Lievens,Allessandro Re,Aspasia Stamatoullas,F. Morschhauser,Pieternella J. Lugtenburg,Elisabetta Abruzzese,Pierre Olivier,Rene-Olivier Casasnovas,Gustaaf W. van Imhoff,Tiana Raveloarivahy,Monica Bellei,Thierry Van der Borght,Stéphane Bardet,Annibale Versari,Martin Hutchings,Michel Meignan,Catherine Fortpied +28 more
TL;DR: Combined-modality treatment resulted in fewer early progressions in clinical stage I/II HL, although early outcome was excellent in both arms.
Journal ArticleDOI
Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network
Olivier Hermine,Olivier Hermine,Eva Hoster,Jan Walewski,André Bosly,Stephan Stilgenbauer,Catherine Thieblemont,Michal Szymczyk,Reda Bouabdallah,Michael Kneba,Michael Hallek,Gilles Salles,Pierre Feugier,Vincent Ribrag,Josef Birkmann,Roswitha Forstpointner,Corinne Haioun,Mathias Hänel,Rene-Olivier Casasnovas,Jürgen Finke,Norma Peter,Kamal Bouabdallah,Catherine Sebban,Thomas Fischer,Ulrich Dührsen,Bernd Metzner,Georg Maschmeyer,Lothar Kanz,Christian Schmidt,Richard Delarue,Nicole Brousse,Wolfram Klapper,Elizabeth Macintyre,Marie-Hélène Delfau-Larue,Christiane Pott,Wolfgang Hiddemann,Michael Unterhalt,Martin Dreyling +37 more
TL;DR: Investigating whether the introduction of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation (ASCT) improves outcome found it should be considered standard of care in patients aged 65 years or younger with mantle cell lymphoma.
Journal ArticleDOI
Circulating Tumor DNA Measurements As Early Outcome Predictors in Diffuse Large B-Cell Lymphoma
David M. Kurtz,Florian Scherer,Florian Scherer,Michael C. Jin,Joanne Soo,Alexander F.M. Craig,Mohammad Shahrokh Esfahani,Jacob J. Chabon,Henning Stehr,Chih Long Liu,Robert Tibshirani,Lauren S. Maeda,Neel K. Gupta,Michael S. Khodadoust,Ranjana H. Advani,Ronald Levy,Aaron M. Newman,Ulrich Dührsen,Andreas Hüttmann,Michel Meignan,Rene-Olivier Casasnovas,Jason R. Westin,Mark Roschewski,Wyndham H. Wilson,Gianluca Gaidano,Davide Rossi,Davide Rossi,Maximilian Diehn,Ash A. Alizadeh +28 more
TL;DR: Pretreatment ctDNA levels and molecular responses are independently prognostic of outcomes in aggressive lymphomas, and these risk factors could potentially guide future personalized risk-directed approaches.
Journal ArticleDOI
SUVmax reduction improves early prognosis value of interim positron emission tomography scans in diffuse large B-cell lymphoma.
Rene-Olivier Casasnovas,Michel Meignan,Alina Berriolo-Riedinger,Stéphane Bardet,Anne Julian,Catherine Thieblemont,Pierre Vera,Serge Bologna,Josette Brière,Jean-Philippe Jais,Corinne Haioun,Bertrand Coiffier,Franck Morschhauser +12 more
TL;DR: Analysis of sequential interim PET is feasible for high-risk DLBCL and better predicts outcome than visual analysis, and Maximal standardized uptake value reduction may better predict outcome.
Journal ArticleDOI
Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma
Franck Morschhauser,Nathan Fowler,Pierre Feugier,Reda Bouabdallah,Hervé Tilly,M Palomba,Christophe Fruchart,Edward N. Libby,Rene-Olivier Casasnovas,Ian W. Flinn,Corinne Haioun,Hervé Maisonneuve,Loic Ysebaert,Nancy L. Bartlett,Kamal Bouabdallah,Pauline Brice,Vincent Ribrag,Nicolas Daguindau,Steven Le Gouill,Gian Matteo Pica,Alejandro Martin Garcia-Sancho,Armando Lopez-Guillermo,Jean-François Larouche,Kiyoshi Ando,Maria Gomes da Silva,M. Andre,Pierre Zachee,Laurie Sehn,Kensei Tobinai,Guillaume Cartron,David Liu,Jianming Wang,Luc Xerri,Gilles Salles +33 more
TL;DR: Among patients with previously untreated follicular lymphoma, efficacy results were similar with rituximab plus lenalidomide and ritudinab plus chemotherapy (with both regimens followed by ritukimab maintenance therapy).